Navigation Links
Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
Date:5/22/2012

CAMBRIDGE, Mass. (May 22, 2012) Pushed to the brink of survival, the hyper-driven cells of a cancerous tumor tap into an ancient system that has helped organisms cope with internal stresses and environmental challenges since life began. As an integral part of this system, heat shock protein 90 (HSP90) has been shown to help malignant cells accommodate the genetic changes and profound disturbances in normal biology that occur in cancers.

Researchers have theorized that inhibiting HSP90 just might render breast cancer cells less likely to escape the challenge posed by cutting off their ability to use estrogen. Such is the rationale for a new clinical trial that has begun enrolling patients this week.

In the trial, patients with recurrent or metastatic estrogen receptor-positive (ER+) breast cancer will be treated either with fulvestrant, a drug currently marketed by AstraZeneca as Faslodex, or with a combination of fulvestrant and ganetespib, a drug which inhibits HSP90 and is now in clinical development by Synta Pharmaceuticals.

The trial's principal investigator is Nancy Lin, the Clinical Director of the Breast Oncology Center at Dana-Farber Cancer Institute and Assistant Professor at Harvard Medical School. Lin is collaborating with Luke Whitesell, an oncologist and senior research scientist in the lab of Whitehead Institute Member Susan Lindquist.

Breast cancer is the most common cause of cancer-related deaths in women worldwide. An estimated 40,000 women in the United States are expected to die from the disease this year. In the developed world, approximately two-thirds of all breast cancer cases are ER+. Highly dependent on their estrogen receptors for growth and survival, these tumor cells are sensitive to hormonal therapies, making drugs like tamoxifen and fulvestrant effective first-line therapies for many patients.

However, in patients with breast cancers that recur or metastasize after initial hormonal
'/>"/>

Contact: Nicole Giese Rura
rura@wi.mit.edu
617-258-6851
Whitehead Institute for Biomedical Research
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
2. Low forms of cyclin E reduce breast cancer drugs effectiveness
3. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
4. For Some Breast Cancer Patients, Shorter Radiation Works Well
5. Short-term radiation therapy successful on breast cancer
6. Few Women at High Risk for Breast Cancer Take Tamoxifen
7. Hormone May Prevent Aggressive Breast Cancer
8. MSU researcher linking breast cancer patients with alternative therapies
9. MRI May Not Add Value to Routine Breast Cancer Care
10. Breast Cancer Stats Differ Racially Despite Similar Mammogram Rates
11. Businesses Rally Big Efforts to Benefit the Susan G. Komen Phoenix Affiliates Fight Against Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Omaha, Nebraska (PRWEB) October 22, 2014 ... Travel Nurse staffing company, is happy to announce ... been named to Staffing Industry Analysts’ Staffing 100 ... list, featuring the “100 most influential people in ... Anderson’s leadership, Medical Solutions, the 13th-largest healthcare staffing ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Shriners Hospitals ... that will change the current location of Shriners Hospitals ... South Limestone across from the University of Kentucky Albert ... state-of-the-art ambulatory care center, owned and operated by Shriners ... orthopaedic needs of children and their families well into ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most distinguished ... announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best ... world. , “iPower is one of the most reliable ... kinds of useful products for new and old clients. ... service and a number of features which will appeal ...
(Date:10/22/2014)... Richard Carlson, Managing Partner of Blue ... over 25 years experience. Mr. Carlson is a ... related to EDI, B2B Commerce, RFID and Internet/Intranet technology. ... Board member for Pharmaceutical Commerce Magazine and a Gerson ... is a management and technology consulting firm focused solely ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... may lead to increased blood pressure, according to a new ... in blood pressure for young adult women or for teenagers, ... drank lightly or moderately, their risk of high blood pressure ... parallels studies in older adult men and women," said lead ...
Breaking Medicine News(10 mins):Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... ... retailer, announced today it is giving away 10,000 free business card pens. , ... (PRWEB) December 2, 2009 -- National Pen ... 10,000 free business card pens. , , , , ,“We have a new way to ...
... ... direct microwave signal transmissions away from users will be available in early 2010 from ... ... signal transmissions away from users will be available in early 2010 from Aerius International ...
... ... Sunday, more than 900 runners and walkers from Las Vegas and around ... Las Vegas Half Marathon powered by Zappos.com, raising over $3.2 million for ... Challenge (www.ccteamchallenge). As the official charity of the race, the funds will ...
... , CHICAGO, Dec. 2 The American Health Information ... Dowling, PhD, will be the next chief executive of ... Dowling,s extensive health information experience includes academia, systems management, ... He is scheduled to take office January 13, ...
... , WASHINGTON, Dec. 2 ... their campaign against the U.S. House bill,s pro-life Stupak-Pitts Amendment. ... Yoest released this statement in response to the abortion lobby,s ... abortion with health care, the feminist groups and the abortion ...
... , Ad in Today,s Washington ... If the Catholic bishops have their way, many medical ... The pressure that the US bishops have brought to bear on ... this morning,s Washington Post warns of the likely impact if ...
Cached Medicine News:Health News:National Pen Giving Away 10,000 Business Card Pens 2Health News:New AERIUS Cell Phones Direct Microwave Signals Away from Users 2Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 2Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 3Health News:Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis 4Health News:Dr. Alan F. Dowling Named AHIMA's Next Chief Executive Officer 2Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2
(Date:10/22/2014)... Calif. , Oct. 22, 2014  Paper ... products, has developed APLS ® Body Guard ... minimizes the spread of bacteria and virus while ... APLS Body Guard Bio features a rugged, external ... edges that create a leak-proof inner chamber that ...
(Date:10/22/2014)... October 22, 2014 Oramed ... a clinical-stage pharmaceutical company focused on the development ... top-line clinical results from its Phase IIa clinical ... capsules, to treat type 1 diabetes. The trial was ... under a U.S. Food and Drug Administration ...
(Date:10/22/2014)... --  Surefire Medical , Inc., the developer of a ... delivery of embolization agents in minimally invasive direct-to-tumor interventional ... R. Daniels , MD of the University of Southern ... Steven C. Katz , MD of the Roger Williams ... (SAB).    "The role of the SAB ...
Breaking Medicine Technology:New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
The SE-9000 automated hematology analyzer provides accurate and precise CBC result including a fully automated WBC 5-part differential, and comprehensive test results for enhanced screening ability....
The XE-2100 automated hematology analyzer features new hematology parameters as NRBC, IRF, and HPC that offer valuable and accurate clinical information....
... utilize the infinity-corrected optical system for improved ... has taken this one step further with ... with the capability of a fluorescence illuminator ... imaging and video monitoring. The CKX41 is ...
... The CX31 continue the ... the CH2 microscopes in ... now with UIS infinity-corrected ... improve all-around performance and ...
Medicine Products: